Company profile for Auspex Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders and other rare diseases, including orphan diseases, which are rare diseases that affect fewer than 200,000 people in the United States. Our pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal invo...
Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders and other rare diseases, including orphan diseases, which are rare diseases that affect fewer than 200,000 people in the United States. Our pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, and tardive dyskinesia and Tourette syndrome, subsets of either of which may be deemed to be orphan diseases, as well as other orphan indications. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3333 North Torrey Pines Court Suite 400 La Jolla, CA 92037
Telephone
Telephone
+1 858-558-2400
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://in.reuters.com/article/us-usa-sarshar-insider-trading/us-charges-founder-of-drug-company-bought-by-teva-in-insider-trading-case-idINKBN25L2LD

J.Stempel REUTERS
26 Aug 2020
PureTech eyes clinical trial in long-term COVID-19 complications
PureTech eyes clinical trial in long-term COVID-19 complications

30 May 2020

// Nick P. Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/puretech-eyes-clinical-trial-long-term-covid-19-complications

Nick P. Taylor FIERCE BIOTECH
30 May 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty